Fresh off presenting positive new mechanistic data on its lead candidate, seladelpar, at the 2018 International Liver Congress in Paris, Cymabay Therapeutics Inc. said patient screening for a phase IIb proof-of-concept study of the drug in nonalcoholic steatohepatitis (NASH) is now underway. Enrollment is estimated to take about 12 months, with a top-line readout expected in the second half of 2019, Cymabay's CEO and president, Sujal Shah, told BioWorld.